News for Diurnal Group plc (DNL.L)

New CAHtalyst™ Pediatric and CAHtalyst™ Adult Phase 3 Clinical Study Data in Congenital Adrenal HyperplasiaCAHtalog™ Registry Data Highlighting Impact of Supraphysiologic Glucocorticoid...

/PRNewswire/ -- Diurnal Ltd., a Neurocrine Biosciences company (Nasdaq: NBIX), today announced that it will present new post hoc analyses of Phase 3 extension...

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, today announced that it will present new...

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and fiscal year ended December 31,...

INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $399 MillionINGREZZA® (valbenazine) 2023 Net Product Sales Guidance of $1.67 - $1.77 B...

16 December 2022 HARGREAVE HALE AIM VCT PLC Full Year Results and Notice of AGM Hargreave Hale AIM VCT plc announces its results for the year ended 30 September 2022. The... | December 19, 2022

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2022 and raised net...

The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: ---------- Tullow Oil PLC - London-based oil and gas exploration... | October 28, 2022

Octopus AIM VCT plc Half-Yearly Results Octopus AIM VCT plc is a venture capital trust which aims to provide shareholders with attractive tax-free dividends and long-term capital growth by... | October 26, 2022

The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: ---------- ThinkSmart Ltd - Perth, Australia-based digital payments... | October 21, 2022

Octopus AIM VCT 2 plc Half-Yearly Results Octopus AIM VCT 2 plc (the “Company”) is a venture capital trust (“VCT”) which aims to...

Octopus AIM VCT plc Final Results Octopus AIM VCT plc today announces the final results for the year ended 28 February 2022. Octopus AIM VCT plc...

Hargreave Hale AIM VCT plc(the ‘Company’)(LEI: 213800LRYA19A69SIT31) FULL YEAR RESULTS AND NOTICE OF AGM Hargreave Hale AIM VCT plc announces its...

Octopus AIM VCT 2 plc 18 August 2021 Portfolio Update The investment portfolio of Octopus AIM VCT 2 plc (the "Company") as at 18 August 2021 is as...

Posted on Tuesday, 02/Feb/2021 Posted by michelle Peer-reviewed data from largest ever completed interventional clinical trial in CAH Authors conclude that Chronocort?... | February 2, 2021

DEER PARK, Ill., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ:ETON), a specialty pharmaceutical company focused on developing and ...